Why Novavax’s COVID Vaccine Results Were So Stellar

Novavax (NASDAQ: NVAX) lags behind bigger players in the COVID-19 vaccine arena such as Pfizer and Moderna. However, in late January the biotech announced very promising results from a late-stage study of its experimental coronavirus vaccine. In this Motley Fool Live video recordRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario